MXPA05005286A - Compositions for treating and/or preventing diseases characterized by the presence of metal ions. - Google Patents

Compositions for treating and/or preventing diseases characterized by the presence of metal ions.

Info

Publication number
MXPA05005286A
MXPA05005286A MXPA05005286A MXPA05005286A MXPA05005286A MX PA05005286 A MXPA05005286 A MX PA05005286A MX PA05005286 A MXPA05005286 A MX PA05005286A MX PA05005286 A MXPA05005286 A MX PA05005286A MX PA05005286 A MXPA05005286 A MX PA05005286A
Authority
MX
Mexico
Prior art keywords
composition
certain
blood
brain
organosilicon compound
Prior art date
Application number
MXPA05005286A
Other languages
Spanish (es)
Inventor
David Alan Kew
Original Assignee
Grenpharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grenpharma Llc filed Critical Grenpharma Llc
Publication of MXPA05005286A publication Critical patent/MXPA05005286A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Abstract

The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including organosilicon compounds. A composition of the invention may be administered to a mammal, such as a human. In some cases, the composition may include a silanol, a silandiol, a silantriol, or a cyclic organosilane, and/or be able to form a silanol, a silandiol, or a silantriol upon exposure to physiological conditions such as are found in the blood, in the stomach and/or gastrointestinal tract, or in the brain or other organ. In certain cases, the organosilicon compound may be bound to a moiety able to be transported across the blood-brain barrier into the brain, for example, an amino acid, a peptide, a protein, a virus, etc. The organosilicon compound may also be labeled (e.g., fluorescently or radioactively) in certain instances. In some embodiments, the composition, or a portion thereof, may sequester aluminum or other ions, for example, by electrostatically binding to aluminum ions. The composition may also include other functionalities such as amines, certain alkyl and/or aryl moieties (including substituted alkyls and/or aryls), or hydrophobic moieties, for example, to facilitate transport of the organosilicon compound through the blood-brain barrier.
MXPA05005286A 2002-11-18 2003-11-18 Compositions for treating and/or preventing diseases characterized by the presence of metal ions. MXPA05005286A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US42720102P 2002-11-18 2002-11-18
US42710402P 2002-11-18 2002-11-18
US42720302P 2002-11-18 2002-11-18
US42710502P 2002-11-18 2002-11-18
US45634503P 2003-03-20 2003-03-20
US0336749 2003-11-17
PCT/US2003/037037 WO2004045552A2 (en) 2002-11-18 2003-11-18 Compositions for treating and/or preventing diseases characterized by the presence of metal ions

Publications (1)

Publication Number Publication Date
MXPA05005286A true MXPA05005286A (en) 2006-02-22

Family

ID=34382290

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005286A MXPA05005286A (en) 2002-11-18 2003-11-18 Compositions for treating and/or preventing diseases characterized by the presence of metal ions.

Country Status (5)

Country Link
JP (1) JP2006526567A (en)
AU (1) AU2003298673A1 (en)
CA (1) CA2506231A1 (en)
MX (1) MXPA05005286A (en)
WO (1) WO2004045552A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595308B2 (en) 2002-11-18 2009-09-29 Grenpharma Llc Compositions for treating and/or preventing diseases characterized by the presence of metal ions
US7347970B2 (en) * 2004-02-13 2008-03-25 University Of Florida Research Foundation, Inc. Biocides based on silanol terminated silanes and siloxanes
US7960576B2 (en) 2004-08-13 2011-06-14 Momentive Performance Materials Inc. Diol-derived organofunctional silane and compositions containing same
US7928258B2 (en) 2004-08-20 2011-04-19 Momentive Performance Materials Inc. Cyclic diol-derived blocked mercaptofunctional silane compositions
EP1812013A1 (en) * 2004-10-22 2007-08-01 Grenpharma LLC Compositions for treating and/or preventing diseases characterized by the presence of the metal ions
US7510670B2 (en) 2006-02-21 2009-03-31 Momentive Performance Materials Inc. Free flowing filler composition based on organofunctional silane
US7504456B2 (en) 2006-02-21 2009-03-17 Momentive Performance Materials Inc. Rubber composition containing organofunctional silane
US7919650B2 (en) 2006-02-21 2011-04-05 Momentive Performance Materials Inc. Organofunctional silanes and their mixtures
US7718819B2 (en) 2006-02-21 2010-05-18 Momentive Performance Materials Inc. Process for making organofunctional silanes and mixtures thereof
US8008519B2 (en) 2006-08-14 2011-08-30 Momentive Performance Materials Inc. Process for making mercapto-functional silane
US8097744B2 (en) 2006-08-14 2012-01-17 Momentive Performance Materials Inc. Free flowing filler composition comprising mercapto-functional silane
US8026108B1 (en) * 2006-10-19 2011-09-27 The University Of Central Florida Research Foundation, Inc. Detection of biotargets using bioreceptor functionalized nanoparticles
US7816435B2 (en) 2007-10-31 2010-10-19 Momentive Performance Materials Inc. Halo-functional silane, process for its preparation, rubber composition containing same and articles manufactured therefrom

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039666A (en) * 1975-12-15 1977-08-02 Dow Corning Corporation Anticonvulsant phenylsilanes
US5384312A (en) * 1987-05-08 1995-01-24 Merrell Dow Pharmaceuticals Inc. Substituted silyl alkylene amines
JPH06509103A (en) * 1991-07-15 1994-10-13 アルベマール・コーポレーシヨン Preventing and reducing the severity of traumatic injuries
US5523295A (en) * 1994-07-06 1996-06-04 Brandeis University Method for treating and preventing alzheimer's disease
FR2725208B1 (en) * 1994-09-30 1996-11-29 Exsymol Sa PROCESS FOR THE PREPARATION OF BIOLOGICALLY ACTIVE SILICON COMPOUNDS IN CONCENTRATED FORM
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
JPH10101569A (en) * 1996-10-01 1998-04-21 Eisai Co Ltd Antacid
US5859277A (en) * 1997-06-25 1999-01-12 Wisconsin Alumni Research Foundation Silicon-containing solid support linker

Also Published As

Publication number Publication date
CA2506231A1 (en) 2004-06-03
AU2003298673A1 (en) 2004-06-15
WO2004045552A2 (en) 2004-06-03
WO2004045552A3 (en) 2005-08-18
JP2006526567A (en) 2006-11-24

Similar Documents

Publication Publication Date Title
MXPA05005286A (en) Compositions for treating and/or preventing diseases characterized by the presence of metal ions.
Sun et al. Bismuth in medicine
RU2451029C2 (en) Insulin derivative
CA2455863A1 (en) Tetrahydroquinoline derivatives as gamma secretase inhibitors
CN109912683A (en) A kind of cytotoxic molecule, conjugate and its preparation method and application
BRPI0416656A (en) pyrrolopyrimidine compounds useful in cancer treatment
DE602004014791D1 (en) PHENYLIC ACIDIC ACID AMID COMPOUNDS SUITABLE FOR THE TREATMENT OF PAIN
HUP0000492A1 (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
CY1107146T1 (en) METHODS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE (AD)
AU2003270643A8 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
TW200744673A (en) Improved ibandronate formulations
BR0212078A (en) Method of treating or preventing an amyloid-related disease in a patient, pharmaceutical composition, chemical compound, and use of a compound.
IL177069A0 (en) ANTI-EpCAM IMMUNOGLOBULINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
BR0212787A (en) Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition
BR0312768A (en) 5-Ariltetrazole compounds, compositions thereof and uses thereof
RU95112456A (en) Derivatives of n-(3-piperidinylcarbonyl)-beta-alanine as antagonists of platelet activation factor, method of synthesis, pharmaceutical composition and method of treatment
BR0011728A (en) Method of inhibiting aggregation of amyloid protein and image of amyloid deposits
BR0210392A (en) Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
WO2008117730A1 (en) Composition for preventing or treating lung disease
US6468965B1 (en) Pharmaceutical composition for oral administration of a mixture of chelating agents
JPH05501879A (en) Methods of treating HIV and other retroviruses and compounds useful therein
CA2586681A1 (en) Compositions for treating and/or preventing diseases characterized by the presence of the metal ions
JP2004524305A (en) Biotin derivatives and their complexes with chelating agents
ATE214926T1 (en) USE OF (R-(Z))-ALPHA-(METHOXYIMINO)-ALPHA-(1-AZABICYCL (2.2.2.)OCT-3-YL)ACETONITRILE TO INHIBIT AMYLOID BETA-A4 FORMATION IN ALZHEIMER'S DISEASE
BR0213633A (en) Method and compound for treating a disease associated with aberrant leukocyte recruitment and / or activation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal